Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) - Fonseca, V A; Alvarado-Ruiz, R; Raccah, D; Boka, G; Miossec, P; Gerich, J EEFC6018 GetGoal-Mono Study Investigators (Diabetes Care, 2012)